Search results
Showing 9121 to 9122 of 9122 results
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Further treatment option for triple-negative breast cancer recommended
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.